605 related articles for article (PubMed ID: 28816074)
1. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.
Bartkowiak D; Thamm R; Bottke D; Siegmann A; Böhmer D; Budach V; Wiegel T
Acta Oncol; 2018 Mar; 57(3):362-367. PubMed ID: 28816074
[TBL] [Abstract][Full Text] [Related]
2. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.
Bartkowiak D; Bottke D; Thamm R; Siegmann A; Hinkelbein W; Wiegel T
Radiother Oncol; 2016 Jan; 118(1):131-5. PubMed ID: 26653358
[TBL] [Abstract][Full Text] [Related]
3. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.
Bottke D; Bartkowiak D; Siegmann A; Thamm R; Böhmer D; Budach V; Wiegel T
Prostate Cancer Prostatic Dis; 2019 May; 22(2):344-349. PubMed ID: 30487644
[TBL] [Abstract][Full Text] [Related]
4. Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate.
Budäus L; Schiffmann J; Graefen M; Huland H; Tennstedt P; Siegmann A; Böhmer D; Budach V; Bartkowiak D; Wiegel T
Strahlenther Onkol; 2017 Sep; 193(9):692-699. PubMed ID: 28470414
[TBL] [Abstract][Full Text] [Related]
5. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
[TBL] [Abstract][Full Text] [Related]
7. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
[TBL] [Abstract][Full Text] [Related]
8. The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer.
Bartkowiak D; Siegmann A; Böhmer D; Budach V; Wiegel T
BJU Int; 2019 Nov; 124(5):785-791. PubMed ID: 31220400
[TBL] [Abstract][Full Text] [Related]
9. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
[TBL] [Abstract][Full Text] [Related]
10. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S
Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
12. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
[TBL] [Abstract][Full Text] [Related]
14. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy : Long-term follow-up of a single-center survey.
Lohm G; Lütcke J; Jamil B; Höcht S; Neumann K; Hinkelbein W; Wiegel T; Bottke D
Strahlenther Onkol; 2014 Aug; 190(8):727-31. PubMed ID: 24577132
[TBL] [Abstract][Full Text] [Related]
15. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results.
Lohm G; Bottke D; Jamil B; Miller K; Neumann K; Bartkowiak D; Hinkelbein W; Wiegel T
World J Urol; 2013 Apr; 31(2):423-8. PubMed ID: 22460203
[TBL] [Abstract][Full Text] [Related]
17. Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy.
Kang JJ; Reiter RE; Kummer N; DeKernion J; Steinberg ML; King CR
Am J Clin Oncol; 2018 Jan; 41(1):1-5. PubMed ID: 26237192
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
[TBL] [Abstract][Full Text] [Related]
19. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
20. Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?
Tay KJ; Polascik TJ; Howard LE; Salama JK; Schulman AA; Chen Z; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Clin Genitourin Cancer; 2019 Oct; 17(5):e930-e938. PubMed ID: 31257075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
